Your browser is no longer supported. Please, upgrade your browser.
Settings
EDGE Edge Therapeutics, Inc. daily Stock Chart
EDGE [NASD]
Edge Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.11 Insider Own3.10% Shs Outstand34.65M Perf Week3.64%
Market Cap39.50M Forward P/E- EPS next Y-0.15 Insider Trans-8.75% Shs Float23.33M Perf Month-93.19%
Income-64.50M PEG- EPS next Q-0.53 Inst Own39.40% Short Float4.50% Perf Quarter-90.81%
Sales- P/S- EPS this Y-57.70% Inst Trans-18.68% Short Ratio0.71 Perf Half Y-88.82%
Book/sh1.99 P/B0.57 EPS next Y91.80% ROA-50.00% Target Price1.00 Perf Year-87.39%
Cash/sh2.54 P/C0.45 EPS next 5Y- ROE-67.80% 52W Range0.95 - 17.77 Perf YTD-87.83%
Dividend- P/FCF- EPS past 5Y-64.80% ROI- 52W High-93.58% Beta-
Dividend %- Quick Ratio6.90 Sales past 5Y- Gross Margin- 52W Low20.00% ATR0.73
Employees38 Current Ratio6.90 Sales Q/Q- Oper. Margin- RSI (14)18.44 Volatility12.55% 13.74%
OptionableYes Debt/Eq0.33 EPS Q/Q-167.00% Profit Margin- Rel Volume0.73 Prev Close1.20
ShortableYes LT Debt/Eq0.28 EarningsMay 31 BMO Payout- Avg Volume1.48M Price1.14
Recom3.50 SMA20-72.71% SMA50-89.50% SMA200-89.20% Volume1,076,175 Change-5.00%
Jan-18-18Resumed Credit Suisse Outperform $17
Mar-03-17Resumed Leerink Partners Outperform $21
Oct-26-15Initiated Leerink Partners Outperform
Oct-26-15Initiated JMP Securities Mkt Outperform
Oct-26-15Initiated Credit Suisse Outperform
Apr-16-18 02:58PM  EDGE INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Edge Therapeutics, Inc. Investors Business Wire +5.45%
Apr-12-18 08:34PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of Edge Therapeutics, Inc. Investors (EDGE) Business Wire
Apr-04-18 10:56AM  Biotech Stock Roundup: EDGE Falls, ALKS Down, FDA OK's AMGN Drug Label Expansion Zacks +14.71%
Apr-02-18 10:25AM  Edge Therapeutics Loses Edge on Failure of Late-Stage Study Zacks -8.47%
Mar-29-18 05:28PM  EDGE INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Edge Therapeutics, Inc. Investors Business Wire -9.92%
11:32AM  Credit Suisse Slashes Edge Therapeutics Price Target By 94%, Downgrades Stock After Failed Trial Benzinga
09:34AM  Investor Alert: Kaplan Fox Announces Investigation Of Edge Therapeutics, Inc. PR Newswire
06:31AM  Edge Therapeutics And Apricus Biosciences Are Moving: Heres Why Market Exclusive
Mar-28-18 06:18PM  EDGE THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Edge Therapeutics, Inc. To Contact The Firm PR Newswire -91.60%
04:47PM  Why Tesla, Amazon.com, and Edge Therapeutics Slumped Today Motley Fool
12:53PM  Here's Why Edge Therapeutics Stock Collapsed Today Motley Fool
08:49AM  Edge Therapeutics's stock plummets on heavy volume after late-stage drug trial discontinued MarketWatch
07:00AM  Edge Therapeutics Provides Update following Interim Analysis of Phase 3 NEWTON 2 Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage GlobeNewswire
Mar-02-18 01:00AM  Edited Transcript of EDGE earnings conference call or presentation 1-Mar-18 1:30pm GMT Thomson Reuters StreetEvents
Mar-01-18 07:05AM  Edge Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
06:49AM  Edge Therapeutics reports 4Q loss Associated Press
06:30AM  Edge Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
Feb-28-18 09:47AM  When Can We Expect A Profit From Edge Therapeutics Inc (NASDAQ:EDGE)? Simply Wall St.
Feb-26-18 07:00AM  Edge Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results Conference Call on March 1, 2018 GlobeNewswire
Feb-08-18 07:00AM  Edge Therapeutics to Present at Upcoming Investor Conferences in February GlobeNewswire
Dec-29-17 04:05PM  Edge's EG-1962 Phase 3 NEWTON 2 Study Continues as Planned Following Completion of Futility Analysis GlobeNewswire
Nov-28-17 04:26PM  Edited Transcript of EDGE earnings conference call or presentation 1-Nov-17 12:30pm GMT Thomson Reuters StreetEvents
Nov-06-17 07:00AM  Edge Therapeutics to Present at the 26th Annual Credit Suisse Healthcare Conference GlobeNewswire
Nov-01-17 07:55AM  Is Edge Therapeutics Incs (EDGE) Balance Sheet A Threat To Its Future? Simply Wall St.
07:05AM  Edge Therapeutics reports 3Q loss Associated Press
07:00AM  Edge Therapeutics Reports Third Quarter 2017 Financial Results GlobeNewswire
Oct-18-17 07:00AM  Edge Therapeutics Announces Third Quarter Financial Results Conference Call on November 1, 2017 GlobeNewswire
Oct-06-17 07:00AM  Edge Therapeutics to Present at the Neurocritical Care Society 15th Annual Meeting GlobeNewswire
Sep-20-17 07:00AM  Edge Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Sep-19-17 07:00AM  Edge Therapeutics Appoints Rosemary A. Crane, Pharmaceutical Industry Leader, to its Board of Directors GlobeNewswire
Aug-16-17 06:15PM  Edited Transcript of EDGE earnings conference call or presentation 1-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
Aug-01-17 10:59PM  Edge Therapeutics reports 2Q loss Associated Press
06:45AM  Investor Network: Edge Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
06:30AM  Edge Therapeutics Reports Second Quarter 2017 Financial Results and Continued Operational Progress GlobeNewswire
Jul-29-17 06:45AM  3 Biotech Stocks for Enterprising Investors Motley Fool
Jul-18-17 07:00AM  Edge Therapeutics Announces Second Quarter Financial Results Conference Call on August 1, 2017 GlobeNewswire
Jul-06-17 06:30AM  Edge Therapeutics Announces Commercial Supply Agreement for EG-1962 with Oakwood Laboratories GlobeNewswire
Jun-15-17 07:00AM  Edge Therapeutics to Participate in the JMP Securities Life Science Conference GlobeNewswire
Jun-08-17 06:30AM  Edge Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency GlobeNewswire
Jun-02-17 07:00AM  Edge Therapeutics to Present at Jefferies 2017 Global Healthcare Conference GlobeNewswire
May-10-17 07:00AM  Edge Therapeutics to Present at Bank of America Merrill Lynch 2017 Health Care Conference GlobeNewswire
May-04-17 08:45AM  Edited Transcript of EDGE earnings conference call or presentation 3-May-17 12:30pm GMT Thomson Reuters StreetEvents
May-03-17 07:05AM  Investor Network: Edge Therapeutics, Inc. to Host Earnings Call Accesswire
06:36AM  Edge Therapeutics reports 1Q loss Associated Press
06:30AM  Edge Therapeutics Reports First Quarter 2017 Financial Results and Continued Operational Progress GlobeNewswire
Apr-21-17 07:00AM  Edge Therapeutics Announces Conference Call on May 3, 2017 to Discuss First Quarter 2017 Financial Results GlobeNewswire
Apr-19-17 11:30AM  Edge Therapeutics Rises Following Registered Direct Offering Announcement 24/7 Wall St.
06:30AM  Edge Therapeutics Announces $18 Million Registered Direct Offering of Common Stock GlobeNewswire
Mar-29-17 07:00AM  Edge Therapeutics to Present at Needham & Companys 16th Annual Healthcare Conference GlobeNewswire +5.73%
Mar-15-17 04:17PM  EDGE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statem
Mar-13-17 09:25AM  Edge Therapeutics Announces First Patient Randomized in Study of Intracisternal Administration of EG-1962 in Adults with Aneurysmal Subarachnoid Hemorrhage GlobeNewswire
09:17AM  EDGE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Mar-08-17 01:04PM  EDGE THERAPEUTICS, INC. Financials
Mar-03-17 07:00AM  Edge Therapeutics to Present at Cowen and Company 37th Annual Healthcare Conference on March 8, 2017 GlobeNewswire -5.53%
03:25AM  Edited Transcript of EDGE earnings conference call or presentation 2-Mar-17 1:30pm GMT Thomson Reuters StreetEvents
Mar-02-17 08:30AM  Edge Therapeutics Inc Earnings Call scheduled for 8:30 am ET today
07:07AM  Q4 2016 Edge Therapeutics Inc Earnings Release - Time Not Supplied
07:01AM  EDGE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
06:39AM  Edge Therapeutics reports 4Q loss Associated Press
06:30AM  Edge Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Feb-23-17 07:00AM  Edge Therapeutics Announces Conference Call on March 2, 2017 to Discuss Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Feb-21-17 07:00AM  Edge Therapeutics Appoints Alyssa Wyant as Senior Vice President, Regulatory Affairs and Makes Inducement Grant under NASDAQ Rule 5635(c)(4) GlobeNewswire
Feb-17-17 07:00AM  Edge Therapeutics EG-1962 Data To Be Presented at International Stroke Conference 2017 GlobeNewswire
Feb-08-17 07:00AM  Edge Therapeutics to Present at Investor Conferences in February GlobeNewswire
Dec-15-16 10:36AM  Edge Therapeutics, Inc. :EDGE-US: Earnings Analysis: Q3, 2016 By the Numbers : December 15, 2016
Dec-09-16 09:18AM  Edge Therapeutics Announces Publication of Phase 1/2 Data on EG-1962 for the Treatment of Aneurysmal Subarachnoid Hemorrhage in Peer-Reviewed Medical Journal, Stroke GlobeNewswire
Nov-02-16 11:10AM  Edited Transcript of EDGE earnings conference call or presentation 1-Nov-16 12:30pm GMT
07:30AM  Edge Therapeutics to Present at Investor Conferences in November GlobeNewswire
Nov-01-16 08:30AM  Edge Therapeutics Inc Earnings Call scheduled for 8:30 am ET today
07:31AM  EDGE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
07:07AM  Q3 2016 Edge Therapeutics Inc Earnings Release - Time Not Supplied
06:37AM  Edge Therapeutics reports 3Q loss
06:30AM  Edge Therapeutics Reports Third Quarter Financial Results GlobeNewswire
Oct-25-16 07:00AM  Edge Therapeutics to Host Conference Call on November 1, 2016 to Discuss Third Quarter Financial Results GlobeNewswire
Oct-18-16 06:06AM  EDGE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statem
Oct-17-16 08:30AM  Edge Therapeutics Appoints Chief Operating Officer and Makes Inducement Grant under NASDAQ Rule 5635(c)(4) GlobeNewswire
Oct-11-16 02:34PM  Edge Therapeutics, Inc. :EDGE-US: Earnings Analysis: Q2, 2016 By the Numbers : October 11, 2016
Sep-08-16 07:30AM  Edge Therapeutics to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series and Participate in Additional Investor Conferences in September GlobeNewswire +5.73%
Sep-06-16 04:01PM  Edge Therapeutics Announces Additional Pharmacokinetic Data Supporting the Potential Clinical and Health Economic Impact of EG-1962 in Aneurysmal Subarachnoid Hemorrhage GlobeNewswire
Sep-01-16 04:01PM  Edge Therapeutics to Present Additional Data from Phase 1/2 NEWTON Study of EG-1962 at Two Scientific Conferences in September GlobeNewswire
Aug-19-16 10:00AM  Edge Therapeutics, Inc. (Nasdaq: EDGE) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
Aug-04-16 07:11AM  Edited Transcript of EDGE earnings conference call or presentation 3-Aug-16 12:30pm GMT
Aug-03-16 08:30AM  Edge Therapeutics Inc Earnings Call scheduled for 8:30 am ET today
07:31AM  EDGE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
07:07AM  Q2 2016 Edge Therapeutics Inc Earnings Release - Before Market Open
06:48AM  Edge Therapeutics reports 2Q loss
06:30AM  Edge Therapeutics Reports Second Quarter Financial Results and Recent Highlights GlobeNewswire
Aug-02-16 09:55AM  EDGE THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financia
06:30AM  Edge Therapeutics Announces Closing of $20 Million Debt Facility with Hercules Capital, Inc. GlobeNewswire
Aug-01-16 08:33AM  EDGE THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Jul-29-16 06:30AM  Edge Therapeutics Announces First Patient Treated in Phase 3 NEWTON 2 Study of EG-1962 in Adult Patients with Aneurysmal Subarachnoid Hemorrhage GlobeNewswire
Jul-27-16 07:30AM  Edge Therapeutics to Host Conference Call on August 3, 2016 to Discuss Second Quarter Financial Results GlobeNewswire
Jul-06-16 04:30PM  Edge Therapeutics Announces Appointment of Harry J. Sacks, M.D., FAAP, as Vice President, Clinical Development GlobeNewswire
Jun-24-16 04:17PM  EDGE THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -6.32%
Jun-10-16 09:17AM  Will Edge Therapeutics (EDGE) Continue to Surge Higher?
Jun-02-16 01:03PM  Edge Therapeutics, Inc. :EDGE-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016
08:00AM  Edge Therapeutics (EDGE) Catches Eye: Stock Soars 19.4%
07:30AM  Edge Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
May-16-16 03:46PM  EDGE THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
May-13-16 07:30AM  Edge Therapeutics Receives FDA Fast Track Designation for EG-1962 for the Treatment of Subarachnoid Hemorrhage GlobeNewswire
Edge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Its lead product includes EG-1962, a polymer-based microparticle used for the treatment of aneurysmal subarachnoid hemorrhage. The company is also developing EG-1964, as a prophylactic treatment for the management of chronic subdural hematoma to prevent recurrent bleeding on the surface of the brain; and EG-1965, for the prevention of post-operative atrial fibrillation. Edge Therapeutics, Inc. was founded in 2009 and is headquartered in Berkeley Heights, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Macdonald R. LochChief Scientific OfficerMar 22Sale16.412,50041,025570,602Mar 22 04:03 PM
Macdonald R. LochChief Scientific OfficerMar 21Sale16.522,50041,300573,102Mar 21 11:34 AM
Macdonald R. LochChief Scientific OfficerMar 20Sale16.475,00082,350575,602Mar 21 11:34 AM
Macdonald R. LochChief Scientific OfficerMar 19Sale16.662,50041,650580,602Mar 21 11:34 AM
Leuthner Brian APresident and CEOMar 02Sale15.082,50037,70070,236Mar 05 08:19 AM
Leuthner Brian APresident and CEOMar 01Sale14.812,50037,02572,736Mar 05 08:19 AM
Leuthner Brian APresident and CEOFeb 23Sale15.372,50038,42575,236Feb 23 05:28 PM
Macdonald R. LochChief Scientific OfficerFeb 22Sale14.492,50036,225583,102Feb 22 05:00 PM
Leuthner Brian APresident and CEOFeb 22Sale15.472,50038,67577,736Feb 23 05:28 PM
Macdonald R. LochChief Scientific OfficerFeb 21Sale13.825,00069,100585,602Feb 22 05:00 PM
Macdonald R. LochChief Scientific OfficerFeb 20Sale13.755,00068,750590,602Feb 22 05:00 PM
Leuthner Brian APresident and CEOFeb 02Sale12.962,50032,40080,236Feb 02 09:15 PM
Leuthner Brian APresident and CEOFeb 01Sale13.142,50032,85082,736Feb 02 09:15 PM
Leuthner Brian APresident and CEOJan 03Sale10.112,50025,27585,236Jan 03 06:48 PM
Leuthner Brian APresident and CEOJan 02Sale10.112,50025,27587,736Jan 03 06:48 PM
Leuthner Brian APresident and CEODec 05Sale9.682,50024,20090,236Dec 05 05:39 PM
Leuthner Brian APresident and CEODec 04Sale9.972,50024,92592,736Dec 05 05:39 PM
Leuthner Brian APresident and CEODec 01Sale9.922,50024,80095,236Dec 05 05:39 PM
MARCHIO ALBERT N IIChief Accounting & Adm OfficerNov 22Sale10.003,36133,6100Nov 22 03:08 PM
Leuthner Brian APresident and CEONov 03Sale10.862,50027,15097,736Nov 03 05:53 PM
Leuthner Brian APresident and CEONov 02Sale10.942,50027,350100,236Nov 03 05:53 PM
Leuthner Brian APresident and CEONov 01Sale10.922,50027,300102,736Nov 03 05:53 PM
Leuthner Brian APresident and CEOOct 04Sale11.142,50027,850105,236Oct 04 05:52 PM
Leuthner Brian APresident and CEOOct 03Sale10.932,50027,325107,736Oct 04 05:52 PM
Leuthner Brian APresident and CEOOct 02Sale10.812,50027,025110,236Oct 04 05:52 PM
Leuthner Brian APresident and CEOSep 06Sale10.312,50025,775112,736Sep 06 08:01 PM
Leuthner Brian APresident and CEOSep 05Sale9.942,50024,850115,236Sep 06 08:01 PM
Leuthner Brian APresident and CEOSep 01Sale10.372,50025,925117,736Sep 06 08:01 PM
MARCHIO ALBERT N IIChief Accounting & Adm OfficerAug 29Sale10.422,50026,0503,361Aug 29 05:30 PM
MARCHIO ALBERT N IIChief Accounting & Adm OfficerAug 23Sale10.391,00010,3905,861Aug 24 04:11 PM
Leuthner Brian APresident and CEOAug 03Sale10.402,50026,000120,236Aug 03 08:45 PM
Leuthner Brian APresident and CEOAug 02Sale10.532,50026,325122,736Aug 03 08:45 PM
Leuthner Brian APresident and CEOAug 01Sale10.652,50026,625125,236Aug 03 08:45 PM
Leuthner Brian APresident and CEOJul 06Sale10.082,50025,200127,736Jul 06 05:50 PM
Leuthner Brian APresident and CEOJul 05Sale10.212,50025,525130,236Jul 06 05:50 PM
Leuthner Brian APresident and CEOJul 03Sale10.272,50025,675132,736Jul 06 05:50 PM
Leuthner Brian APresident and CEOApr 26Sale11.101001,110135,236May 09 03:33 PM